Lazertinib in patients with EGFR mutation | 合法藥品大搜索

由 MJ Ahn 著作 · 2019 · 被引用 45 次 — Lazertinib (YH25448) is an oral, highly potent, irreversible, third-generation, mutant-selective, and wild-type-sparing EGFR TKI, with half maximal ... Read More

由 S Dhillon 著作 — Lazertinib (LECLAZA®) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and ... Read More

lazertinib. An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, ... Read More

NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying lazertinib. Read More

2021年5月19日 — Lazertinib is an oral, third-generation, brain-penetrant, EGFR TKI that targets both the T790M mutation and activating EGFR mutations while ... Read More

2020年9月21日 — Amivantamab 和lazertinib 聯合一線治療EGFRm NSCLC 反應率達100% ... 接受amivantamab 和lazertinib 治療的患者，在追蹤7 個月中位數（4-7 ... Read More

An arm type in which a group of participants does not receive any intervention/​treatment during the clinical trial. Observational study. A type of clinical study in ... Read More

2020年7月27日 — Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody that targets the extracellular ... Read More

Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for ... Read More